… In the RE-LY clinical trial, dabigatran presented a better effectiveness/ safety profile when …
of the real-world setting. We aimed to assess the performance of dabigatran in real-world …

… 1-year real-life risk of major clinical events with dabigatran or rivaroxaban versus … real-life
effect of dabigatran and rivaroxaban compared with VKAs, as used in the general population. …

… In the RE-LY trial, dabigatran 150 mg twice daily was … dabigatran 110 mg twice daily was
noninferior. Both doses greatly reduced hemorrhagic stroke, and dabigatran 110 mg twice daily …

… to assess the effectiveness and safety of dabigatran (direct thrombin inhibitor) vs.
acenocoumarol (vitamin K antagonist) in patients with atrial fibrillation (AF) in daily clinical practice. …

… In this systematic review, real-world evidence shows that dabigatran is comparable with
warfarin in preventing ischemic stroke in patients with NVAF. However, dabigatran is associated …

… for the comparison between dabigatran and warfarin (Figure 3). The risk of stroke was lower
with dabigatran than warfarin, and this superiority of dabigatran was more pronounced in …

… in real-world settings. The objective of this study is to implement this novel design to evaluate
safety and effectiveness of dabigatran … of dabigatran initiators were switched from warfarin. …

… In elderly patients (≥ 75 years), evidence of dabigatran efficacy is lacking and increased …
effectiveness and safety in elderly patients in real-world practice. We conducted a population-…

… clearly showed a good safety and effectiveness profile of dabigatran in atrial fibrillation …
dabigatran is associated with generally good clinical performance in the Italian real-life population…

… populations, in the real world. Thus, the importance of observational studies in depicting ‘the
real world’ is … at 27,538 dabigatran-rivaroxaban patient pairs. This study which compared …